A Phase 2 interventional study of AR1001 10mg and Placebo in Mild to Moderate Alzheimer's Disease, sponsored by AriBio Co., Ltd.. Completed at 21 sites in United States. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by AriBio Co., Ltd. · Phase 2, Interventional, and Treatment
Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, Kim S, Xi T, Busam JA, Tete B, Choung JJ, Sha SJ. A phase 2 randomized, placebo-controlled study on th…PubMed 40912996 ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 406th largest by enrollment of the 1,610 interventional ones that give a count, is one of 118 that started in 2019, is one of 360 in phase 2, and was the 986th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 55 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,941 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 118 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,610 interventional studies, 160 across the 309 observational. Of the 1,379 that completed or were terminated, 592 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,941 have an industry lead sponsor. The 10 most frequent:
AriBio Co., Ltd. is the lead sponsor of 2 studies on the registry; none are open to participants now.
AriBio Co., Ltd. has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
164 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 164 to your calendar (.ics) → With an account.
Among the 1,941 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks. An optional 26 week extension phase will be available to participants who successfully complete the original phase of the study.
Alzheimer's Disease (AD) is the most prevalent neurodegenerative disorder in The United States affecting approximately 5.4 million Americans. AD is characterized by progressive loss in memory and as well as a decline in the ability to learn that is associated with neuronal death. Well known hallmarks of AD are neuritic plaques and neurofibrillary tangles and extensive inflammation. Currently, no treatment has been developed to fully cure or prevent the progression of dementia that is associated with AD.
AR1001 is a polypharmacological drug candidate being developed as a treatment for AD and shows great potential with favorable attributes for a central nervous system (CNS) drug (i.e., high specificity and potency, as well as good pharmacokinetic, bioavailability, CNS penetration, and ensured safety).
The clinical study of AR1001 aims to evaluate the efficacy and safety of AR1001 as a potential treatment for AD. Based on the preclinical results, AR1001 could be an effective treatment option with a mechanism of action that has not been explored for AD indication.
The criteria were revised on the registry on Nov 19, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Subjects who have history of cancer or malignant tumor within 5 years prior to screening with the exception of:
Extension Phase Continuation Criterion
1. Subjects enrolled in AR1001-ADP2-US01 and completed 26 weeks of assigned dosing.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo, orally administered once daily for 26 weeks.
Drug: Placebo
Active, AR1001 - 10 mg, orally administered once daily for 26 weeks plus a 26 week extension phase.
Drug: AR1001 10mg
Active, AR1001 - 30 mg, orally administered once daily for 26 weeks plus a 26 week extension phase.
Drug: AR1001 30mg
AR1001 Active Oral Tablet 10mg
Also known as: mirodenafil 10mg
Placebo Oral Tablet
AR1001 Active Oral Tablet 30mg
Also known as: Mirodenafil 30mg
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog 13)
The Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog 13) is an assessment of cognition with domains for memory, language, praxis, and orientation. Values frange from 0-85 (higher scores indicate greater cognitive impairment). The total score is the sum of scores across all 13 individual items.
Time frame: Baseline to Week 26
Change From Baseline in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)
The ADSC-CGIC measures change in the areas of mental/cognitive state, behavior, and functioning. ADSC-CGIC is rated on a 7-point Likert-type scale with the following scores: 1 - marked improvement, 2 - moderate improvement, 3 - minimal improvement, 4 - no change, 5 - minimal worsening, 6 - moderate worsening, and 7 - marked worsening.
Time frame: Baseline to Week 26
Change From Baseline in Mini-mental Status Examination 2 (MMSE-2)
The Mini-mental Status Examination, 2nd edition (MMSE-2) measures cognitive impairment. Two versions of the instrument were collected: MMSE-2: BV and MMSE-2: SV. The total possible score of the MMSE-2 BV was 16 points; the total possible score of the MMSE-2: SV was 30 points. Higher scores indicate better cognitive function.
Time frame: Baseline to Week 26
Change From Baseline in Neuropsychiatric Index (NPI)
The NPI measures 10 dementia-related behavioral symptoms and 2 neurovegetative areas of sleep, appetite and eating disorders. The total score are the sum of the products of frequency and severity for each behavioral symptom. Scale ranges from 0-144 with higher scores indicating greater neuropsychiatric severity.
Time frame: Baseline to Week 26
Change From Baseline in Global Depression Scale (GDS)
The GDS measures depression in geriatric subjects with 15 yes/no questions. Each response that indicates despressive symptoms receives a score of 1. Total scores range from 0 (no depression) to 15 (severe depression), with higher scores indicating more depressive symptoms.
Time frame: Baseline to Week 26
Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Family Version
The Quality of Life in Alzheimer's Disease (QoL-AD) scale assesses quality of life in participants with Alzheimer's disease. The Family Version is completed by the participant's caregiver and consists of 13 items, each scored from 1 (poor) to 4 (excellent). The total score is calculated as the sum of all 13 item scores and ranges from 13 to 52, with higher scores indicating better quality of life.
Time frame: Baseline to Week 26
Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Participant Version
The Quality of Life in Alzheimer's Disease (QoL-AD) scale assesses quality of life in participants with Alzheimer's disease. The Participant Version is completed by the participant and consists of 13 items, each scored from 1 (poor) to 4 (excellent). The total score is calculated as the sum of all 13 item scores and ranges from 13 to 52, with higher scores indicating better quality of life.
Time frame: Baseline to Week 26
Treatment Related Adverse Events
Number of subjects with treatment related adverse events during the 26-week treatment phase as assessed by analysis of adverse events including symptoms and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results
Time frame: 26 Weeks
Change From Baseline in ADAS-Cog 13: Monotherapy Subpopulation
ADAS-Cog 13 is an assessment of cognition with domains for memory, language, praxis, and orientation. Values frange from 0-85 (higher scores indicate greater cognitive impairment). The total score is the sum of scores across all 13 individual items.
Time frame: Baseline to Week 26
| Milestone | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Started | 70 | 70 | 70 |
| Completed | 55 | 61 | 57 |
| Not completed | 15 | 9 | 13 |
| Milestone | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Started | 0 | 73 | 68 |
| Completed | 0 | 61 | 54 |
| Not completed | 0 | 12 | 14 |
The Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog 13) is an assessment of cognition with domains for memory, language, praxis, and orientation. Values frange from 0-85 (higher scores indicate greater cognitive impairment). The total score is the sum of scores across all 13 individual items.
| Units on a scale | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog 13) | -1.327 ± 6.799 | -1.667 ± 7.226 | -0.228 ± 7.938 |
The ADSC-CGIC measures change in the areas of mental/cognitive state, behavior, and functioning. ADSC-CGIC is rated on a 7-point Likert-type scale with the following scores: 1 - marked improvement, 2 - moderate improvement, 3 - minimal improvement, 4 - no change, 5 - minimal worsening, 6 - moderate worsening, and 7 - marked worsening.
| Units on a scale | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) | 4.29 ± .126 | 4.19 ± .12 | 4.32 ± .121 |
The Mini-mental Status Examination, 2nd edition (MMSE-2) measures cognitive impairment. Two versions of the instrument were collected: MMSE-2: BV and MMSE-2: SV. The total possible score of the MMSE-2 BV was 16 points; the total possible score of the MMSE-2: SV was 30 points. Higher scores indicate better cognitive function.
| Units on a scale | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Mini-mental Status Examination 2 (MMSE-2) | -0.41 ± 0.305 | -0.03 ± 0.283 | 0.07 ± 0.295 |
The NPI measures 10 dementia-related behavioral symptoms and 2 neurovegetative areas of sleep, appetite and eating disorders. The total score are the sum of the products of frequency and severity for each behavioral symptom. Scale ranges from 0-144 with higher scores indicating greater neuropsychiatric severity.
| Units on a scale | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Neuropsychiatric Index (NPI) | -2.49 ± 1.073 | -1.67 ± 0.990 | -0.62 ± 1.024 |
The GDS measures depression in geriatric subjects with 15 yes/no questions. Each response that indicates despressive symptoms receives a score of 1. Total scores range from 0 (no depression) to 15 (severe depression), with higher scores indicating more depressive symptoms.
| Units on a scale | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Global Depression Scale (GDS) | -0.58 ± 0.281 | -0.03 ± 0.260 | -0.36 ± 0.266 |
The Quality of Life in Alzheimer's Disease (QoL-AD) scale assesses quality of life in participants with Alzheimer's disease. The Family Version is completed by the participant's caregiver and consists of 13 items, each scored from 1 (poor) to 4 (excellent). The total score is calculated as the sum of all 13 item scores and ranges from 13 to 52, with higher scores indicating better quality of life.
| Units on a scale | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Family Version | 1.07 ± 0.656 | 0.93 ± 0.616 | 0.52 ± 0.621 |
The Quality of Life in Alzheimer's Disease (QoL-AD) scale assesses quality of life in participants with Alzheimer's disease. The Participant Version is completed by the participant and consists of 13 items, each scored from 1 (poor) to 4 (excellent). The total score is calculated as the sum of all 13 item scores and ranges from 13 to 52, with higher scores indicating better quality of life.
| Units on a scale | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Quality of Life in Alzheimer's Disease (QoL-AD) -- Participant Version | 0.17 ± 0.624 | 0.23 ± 0.574 | 0.36 ± 0.583 |
pTau181 is a biomarker whose levels have been shown to correlate with Alzheimer's disease severity. Levels of pTau181 were determined from plasma samples.
| pg/mL | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Phosphorylated Tau 181 (pTau181) | 0.306 ± 0.195 | -0.294 ± 0.275 | -0.459 ± 0.288 |
Aβ 42/40 ratio is a biomarker that measures the relative levels of two amyloid protein fragments. Higher ratios are better and indicate a lower likelihood of amyloid buildup. Aβ 42/40 was determined from plasma samples.
| Unitless (Ratio) | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Amyloid Beta 42/40 (Aβ 42/40) Ratio | 0.001 ± 0.001 | 0 ± 0.002 | 0.001 ± 0.002 |
Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein primarily found in astrocytes whose levels correlate with severity of Alzheimer's disease. Levels of GFAP were determined from plasma samples.
| pg/mL | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Glial Fibrillary Acidic Protein (GFAP) | 23.895 ± 13.698 | 11.892 ± 12.873 | -7.016 ± 9.540 |
Neurofilament light chain (NfL) is a neuron-specific protein whose levels correlate with severity of Alzheimer's disease. Levels of NfL were determined from plasma samples.
| pg/mL | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Neurofilament Light Chain (NfL) | 1.063 ± 1.858 | 0.952 ± 1.813 | -6.646 ± 6.172 |
pTau217 is a biomarker whose levels have been shown to correlate with Alzheimer's disease severity. Levels of pTau217 were determined from plasma samples.
| pg/mL | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in Phosphorylated Tau 217 (pTau217) | 0.037 ± 0.059 | 0.020 ± 0.040 | -0.118 ± 0.101 |
ADAS-Cog 13 is an assessment of cognition with domains for memory, language, praxis, and orientation. Values frange from 0-85 (higher scores indicate greater cognitive impairment). The total score is the sum of scores across all 13 individual items.
| Units on a scale | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Change From Baseline in ADAS-Cog 13: Monotherapy Subpopulation | -1.756 ± 1.347 | -0.812 ± 1.634 | -3.54 ± 1.257 |
Number of subjects with treatment related adverse events during the 26-week treatment phase as assessed by analysis of adverse events including symptoms and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results
| Participants | Placebo | AR1001 - 10 mg | AR1001 - 30 mg |
|---|---|---|---|
| Treatment Related Adverse Events | 42 | 39 | 47 |
Collected over Over 52 weeks of treatment (26 week treatment + 26 week extension). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/70 (0%) | 6/70 (8.6%) | 14/70 (20%) |
| AR1001 - 10 mg | 1/70 (1.4%) | 6/70 (8.6%) | 7/70 (10%) |
| AR1001 - 30 mg | 0/70 (0%) | 8/70 (11.4%) | 24/70 (34.3%) |
| AR1001 - 10 mg (Extension) | 0/73 (0%) | 2/73 (2.7%) | 10/73 (13.7%) |
| AR1001 - 30 mg (Extension) | 0/68 (0%) | 2/68 (2.9%) | 10/68 (14.7%) |
| Event | Placebo | AR1001 - 10 mg | AR1001 - 30 mg | AR1001 - 10 mg (Extension) | AR1001 - 30 mg (Extension) |
|---|---|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 0/70 | 0/70 | 1/70 | 0/73 | 1/68 |
| Non-cardiac chest painGeneral disorders | 0/70 | 0/70 | 0/70 | 0/73 | 1/68 |
| Transient ischaemic attackNervous system disorders | 0/70 | 0/70 | 0/70 | 0/73 | 1/68 |
| SyncopeNervous system disorders | 1/70 | 0/70 | 1/70 | 0/73 | 0/68 |
| AphasiaNervous system disorders | 1/70 | 0/70 | 0/70 | 0/73 | 0/68 |
| SeizureNervous system disorders | 0/70 | 0/70 | 1/70 | 0/73 | 0/68 |
| Subarachnoid hemorrhageNervous system disorders | 0/70 | 1/70 | 0/70 | 0/73 | 0/68 |
| COVID-19Infections and infestations | 0/70 | 1/70 | 1/70 | 0/73 | 0/68 |
| Abdominal sepsisInfections and infestations | 0/70 | 1/70 | 0/70 | 1/73 | 0/68 |
| Escherichia sepsisInfections and infestations | 0/70 | 0/70 | 1/70 | 0/73 | 0/68 |
| Event | Placebo | AR1001 - 10 mg | AR1001 - 30 mg | AR1001 - 10 mg (Extension) | AR1001 - 30 mg (Extension) |
|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 2/70 | 2/70 | 4/70 | 6/73 | 3/68 |
| DizzinessNervous system disorders | 5/70 | 0/70 | 1/70 | 2/73 | 3/68 |
| NauseaGastrointestinal disorders | 2/70 | 1/70 | 5/70 | 0/73 | 1/68 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/70 | 0/70 | 5/70 | 1/73 | 1/68 |
| FallInjury, poisoning and procedural complications | 2/70 | 2/70 | 5/70 | 1/73 | 1/68 |
| HeadacheNervous system disorders | 3/70 | 2/70 | 4/70 | 0/73 | 1/68 |
| Age, Continuous(years) | Placebo | AR1001 - 10 mg | AR1001 - 30 mg | Total |
|---|---|---|---|---|
| Mean | 70.4 (58 to 80) | 70.9 (55 to 81) | 70.4 (55 to 80) | 70.6 (55 to 81) |
| Sex: Female, Male(Participants) | Placebo | AR1001 - 10 mg | AR1001 - 30 mg | Total |
|---|---|---|---|---|
| Female | 48 | 43 | 47 | 138 |
| Male | 22 | 27 | 23 | 72 |
| Race (NIH/OMB)(Participants) | Placebo | AR1001 - 10 mg | AR1001 - 30 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 12 | 8 | 8 | 28 |
| White | 58 | 60 | 62 | 180 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | AR1001 - 10 mg | AR1001 - 30 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 13 | 13 | 16 | 42 |
| Not Hispanic or Latino | 56 | 57 | 52 | 165 |
| Unknown or Not Reported | 1 | 0 | 2 | 3 |
| Region of Enrollment(Participants) | Placebo | AR1001 - 10 mg | AR1001 - 30 mg | Total |
|---|---|---|---|---|
| United States | 70 | 70 | 70 | 210 |
| Baseline ADAS-Cog13 Score(Units on a scale) | Placebo | AR1001 - 10 mg | AR1001 - 30 mg | Total |
|---|---|---|---|---|
| Mean | 24.57 ± 9.96 | 25.23 ± 9.62 | 26.31 ± 11.03 | 25.37 ± 10.19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in Dec 2020, 20 months.
Results were first posted in Nov 2026, 5 years 10 months after primary completion.
Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 20 months is below that.
Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, Kim S, Xi T, Busam JA, Tete B, Choung JJ, Sha SJ. A phase 2 randomized, placebo-controlled study on th…PubMed 40912996 ↗
Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, Kim S, Xi T, Busam JA, Tete B, Choung JJ, Sha SJ. A phase 2 randomized, placebo-controlled study on th…PubMed 40912996 ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.